Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · View financials
Decision snapshot: CRH stock price vs MDT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MDT's multiple
Needs MDT P/E.
Implied fair value · at CRH's multiple
Needs CRH P/E.
Live quote
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: CRH FY 2025 (ended Dec 31, 2025) · MDT FY 2026 (ended Apr 24, 2026). Fiscal years are not aligned.
Trendline
11 fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
CRH public limited company · implied price per share
Bear
$61.82
Base
$72.72
Bull
$83.63
Medtronic plc · implied price per share
Bear
$44.00
Base
$51.76
Bull
$59.52
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.75x
0.57x
Net debt / EBITDA
Leverage against operating earnings
1.75x
1.78x
Cash and equivalents
Liquid reserves on the balance sheet
$4.10B
$9.22B
Total debt
Interest-bearing obligations outstanding
$18.71B
$27.96B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe CRH can sustain its higher ROIC of 13.7% while improving growth from 5.3% and maintaining balance-sheet discipline, then the current price looks attractive versus MDT because CRH still trades at lower P/E, P/S, and EV/EBITDA multiples despite solid quality metrics.
CRH trades at a clear valuation discount to MDT on every listed multiple, with a P/E of 17.0x versus 22.3x and EV/EBITDA of 9.3x versus 11.9x. The implied price of $140.68 suggests 30.8% upside, but CRH is already near the upper half of its historical band and close to the top of its DCF range.
Supporting Metrics
